Strategies for vaccination against Epstein–Barr virus-associated diseases


    loading  Checking for direct PDF access through Ovid

Abstract

The association of the Epstein–Barr virus (EBV) to diseases with high morbidity and mortality provides evidence for the necessity of a vaccine to prevent infection or to reduce the burden of infection. Vaccine prototypes such as recombinant subunit vaccines, peptide epitope-based vaccines, recombinant virus vector-based vaccines, DNA vaccines, and EBV life vaccines have been developed for protective vaccination as well as for therapeutic vaccination and successfully tested in vitro and in animal model. Phase I and phase II human trials have been performed for a few of these strategies with no significant adverse effects being observed. Sterile immunity and prevention of infection were not achieved so far, but efficiency against EBV-associated diseases could be demonstrated.

    loading  Loading Related Articles